(Q40227841)

English

Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L.

scientific article published on 12 April 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 September 2017

Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L. (English)

1 reference

Europe PubMed Central

18 September 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

Marina G Tarakanovskaya

1

1 reference

Europe PubMed Central

18 September 2017

Jigjidsuren Chinburen

2

1 reference

Europe PubMed Central

18 September 2017

Purev Batchuluun

3

1 reference

Europe PubMed Central

18 September 2017

Chogsom Munkhzaya

4

1 reference

Europe PubMed Central

18 September 2017

Genden Purevsuren

5

1 reference

Europe PubMed Central

18 September 2017

Dorjiin Dandii

6

1 reference

Europe PubMed Central

18 September 2017

Tsogkhuu Hulan

7

1 reference

Europe PubMed Central

18 September 2017

Dandii Oyungerel

8

1 reference

Europe PubMed Central

18 September 2017

Galyna A Kutsyna

9

1 reference

Europe PubMed Central

18 September 2017

Alan A Reid

10

1 reference

Europe PubMed Central

18 September 2017

Vika Borisova

11

1 reference

Europe PubMed Central

18 September 2017

Allen I Bain

12

1 reference

Europe PubMed Central

18 September 2017

Vichai Jirathitikal

13

1 reference

Europe PubMed Central

18 September 2017

Aldar S Bourinbaiar

14

1 reference

Europe PubMed Central

18 September 2017

publication date

12 April 2017

1 reference

Europe PubMed Central

18 September 2017

Journal of hepatocellular carcinoma

1 reference

Europe PubMed Central

18 September 2017

4

1 reference

Europe PubMed Central

18 September 2017

59-69

1 reference

Europe PubMed Central

18 September 2017

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

1 April 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

The Basis of Oncoimmunology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Status of and prospects for cancer vaccines against hepatocellular carcinoma in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

The Global Burden of Cancer 2013

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Status quo of chronic liver diseases, including hepatocellular carcinoma, in Mongolia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Immune approaches in tuberculosis therapy: a brief overview

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Cancer incidence and mortality in Mongolia - National Registry Data.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Hepatitis B and C virus infections in hepatocellular carcinoma and cirrhosis in Mongolia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Immunity, Inflammation, and Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Clinical experience with therapeutic vaccines designed for patients with hepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Design and endpoints of clinical trials in hepatocellular carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Oral vaccination: where we are?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Phase I clinical trial of targeted therapy using 131I-Hepama-1 mAb in patients with hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Spontaneous necrosis of hepatocellular carcinoma: a case report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Inflammation and cancer: back to Virchow?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

22 September 2017

Spontaneous regression of hepatocellular carcinoma: its imaging course leading to complete disappearance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

25 September 2017

Spontaneous regression of a large hepatocellular carcinoma: case report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

17 June 2018

Clinical features and prognosis of hepatocellular carcinoma in Mongolia: a multicentre study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

20 August 2018

A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

20 August 2018

Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

20 August 2018

Current situation of hepatocellular carcinoma in Mongolia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

20 August 2018

Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

20 August 2018

Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

20 August 2018

Open-label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

20 August 2018

High frequency of hepatocellular carcinoma in Mongolia; association with mono-, or co-infection with hepatitis C, B, and delta viruses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

20 August 2018

Hepatocellular carcinoma and its early detection by AFP testing in Mongolia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5396941

20 August 2018

Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28443252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mongolia's struggle with liver cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28443252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Spontaneous regression of hepatocellular carcinoma confirmed by surgical specimen: report of two cases and review of the literature

1 reference

https://pubmed.ncbi.nlm.nih.gov/28443252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/28443252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II Randomized Trial of Autologous Formalin-Fixed Tumor Vaccine for Postsurgical Recurrence of Hepatocellular Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28443252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical outcome and prognostic factors of patients with hepatocellular carcinoma and extrahepatic metastasis treated with sorafenib

1 reference

https://pubmed.ncbi.nlm.nih.gov/28443252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2147/JHC.S122507

1 reference

Europe PubMed Central

18 September 2017

1 reference

Europe PubMed Central

18 September 2017

1 reference

Europe PubMed Central

18 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40227841&oldid=1847392990"